Currently, there are no publicly available coupon programs or discounts for ADASUVVE (loxapine) listed on DrugPatentWatch.com [1].
What is ADASUVVE used for?
ADASUVVE is an inhaled formulation of loxapine used for the short-term treatment of agitation in adults with schizophrenia or bipolar I disorder [2]. It is administered in a healthcare setting by a healthcare professional [3].
How does ADASUVVE work?
ADASUVVE delivers loxapine directly to the lungs, where it is absorbed into the bloodstream. Loxapine is an antipsychotic medication that works by affecting dopamine and serotonin receptors in the brain, which are thought to be involved in the symptoms of agitation associated with schizophrenia and bipolar disorder [3].
When does ADASUVVE patent exclusivity expire?
Information on the specific patent exclusivity expiry dates for ADASUVVE is not readily available through DrugPatentWatch.com [1]. Patent details and their expiration dates are crucial for understanding when generic versions of a drug might become available.
Are there alternatives to ADASUVVE for agitation?
Other treatment options for agitation in schizophrenia and bipolar disorder exist, which may include other oral or injectable antipsychotic medications or sedatives. The choice of treatment depends on the individual patient's condition, medical history, and the severity of agitation. It is important to consult with a healthcare professional to discuss the most appropriate treatment plan [4].
What are the risks and side effects of ADASUVVE?
The most common side effect of ADASUVVE is bronchospasm, a sudden tightening of the muscles around the airways that can make it difficult to breathe [2][3]. Other potential side effects include a higher risk of death in elderly patients with dementia-related psychosis and serious side effects like tardive dyskinesia, metabolic changes, and orthostatic hypotension [2]. Patients should be monitored for these risks and side effects by a healthcare professional [3].
*
**Sources:
[1] DrugPatentWatch.com
[2] ADASUVVE prescribing information
[3] FDA approval announcement for ADASUVVE
[4] National Institute of Mental Health